These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 12837807)

  • 1. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.
    Leonard JP; Coleman M; Ketas JC; Chadburn A; Ely S; Furman RR; Wegener WA; Hansen HJ; Ziccardi H; Eschenberg M; Gayko U; Cesano A; Goldenberg DM
    J Clin Oncol; 2003 Aug; 21(16):3051-9. PubMed ID: 12837807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
    Leonard JP; Coleman M; Ketas JC; Chadburn A; Furman R; Schuster MW; Feldman EJ; Ashe M; Schuster SJ; Wegener WA; Hansen HJ; Ziccardi H; Eschenberg M; Gayko U; Fields SZ; Cesano A; Goldenberg DM
    Clin Cancer Res; 2004 Aug; 10(16):5327-34. PubMed ID: 15328168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
    Lindén O; Hindorf C; Cavallin-Ståhl E; Wegener WA; Goldenberg DM; Horne H; Ohlsson T; Stenberg L; Strand SE; Tennvall J
    Clin Cancer Res; 2005 Jul; 11(14):5215-22. PubMed ID: 16033839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
    Leonard JP; Coleman M; Ketas J; Ashe M; Fiore JM; Furman RR; Niesvizky R; Shore T; Chadburn A; Horne H; Kovacs J; Ding CL; Wegener WA; Horak ID; Goldenberg DM
    J Clin Oncol; 2005 Aug; 23(22):5044-51. PubMed ID: 15955901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Final results of a phase I radioimmunotherapy trial using (186)Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma.
    Postema EJ; Raemaekers JM; Oyen WJ; Boerman OC; Mandigers CM; Goldenberg DM; van Dongen GA; Corstens FH
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3995S-4002S. PubMed ID: 14506199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.
    Strauss SJ; Morschhauser F; Rech J; Repp R; Solal-Celigny P; Zinzani PL; Engert A; Coiffier B; Hoelzer DF; Wegener WA; Teoh NK; Goldenberg DM; Lister TA
    J Clin Oncol; 2006 Aug; 24(24):3880-6. PubMed ID: 16864854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma.
    Leonard JP; Schuster SJ; Emmanouilides C; Couture F; Teoh N; Wegener WA; Coleman M; Goldenberg DM
    Cancer; 2008 Nov; 113(10):2714-23. PubMed ID: 18853418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.
    Morschhauser F; Kraeber-Bodéré F; Wegener WA; Harousseau JL; Petillon MO; Huglo D; Trümper LH; Meller J; Pfreundschuh M; Kirsch CM; Naumann R; Kropp J; Horne H; Teoh N; Le Gouill S; Bodet-Milin C; Chatal JF; Goldenberg DM
    J Clin Oncol; 2010 Aug; 28(23):3709-16. PubMed ID: 20625137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
    Carnahan J; Wang P; Kendall R; Chen C; Hu S; Boone T; Juan T; Talvenheimo J; Montestruque S; Sun J; Elliott G; Thomas J; Ferbas J; Kern B; Briddell R; Leonard JP; Cesano A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3982S-90S. PubMed ID: 14506197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.
    Advani A; Coiffier B; Czuczman MS; Dreyling M; Foran J; Gine E; Gisselbrecht C; Ketterer N; Nasta S; Rohatiner A; Schmidt-Wolf IG; Schuler M; Sierra J; Smith MR; Verhoef G; Winter JN; Boni J; Vandendries E; Shapiro M; Fayad L
    J Clin Oncol; 2010 Apr; 28(12):2085-93. PubMed ID: 20308665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
    Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
    Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
    Witzig TE; Wiernik PH; Moore T; Reeder C; Cole C; Justice G; Kaplan H; Voralia M; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Vose JM
    J Clin Oncol; 2009 Nov; 27(32):5404-9. PubMed ID: 19805688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.
    Advani R; Forero-Torres A; Furman RR; Rosenblatt JD; Younes A; Ren H; Harrop K; Whiting N; Drachman JG
    J Clin Oncol; 2009 Sep; 27(26):4371-7. PubMed ID: 19636010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
    Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR
    Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.
    Friedberg JW; Cohen P; Chen L; Robinson KS; Forero-Torres A; La Casce AS; Fayad LE; Bessudo A; Camacho ES; Williams ME; van der Jagt RH; Oliver JW; Cheson BD
    J Clin Oncol; 2008 Jan; 26(2):204-10. PubMed ID: 18182663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study.
    Steinfeld SD; Tant L; Burmester GR; Teoh NK; Wegener WA; Goldenberg DM; Pradier O
    Arthritis Res Ther; 2006; 8(4):R129. PubMed ID: 16859536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD22 as a target of passive immunotherapy.
    Cesano A; Gayko U
    Semin Oncol; 2003 Apr; 30(2):253-7. PubMed ID: 12720147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epratuzumab: targeting B-cell malignancies through CD22.
    Coleman M; Goldenberg DM; Siegel AB; Ketas JC; Ashe M; Fiore JM; Leonard JP
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3991S-4S. PubMed ID: 14506198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.